TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS

TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS Compounds of formula I wherein: R 1 is and R 2 , R 4 , and R 6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase an...

Full description

Saved in:
Bibliographic Details
Main Authors VENKATESAN, ARANAPAKAM, M, AYRAL-KALOUSTIAN, SEMIRAMIS, SHI, MENGXIAO, DELOS SANTOS, EFREN, GUILLERMO, GOPALSAMY, ARIAMALA, CURRAN, KEVIN, J, DOS SANTOS, OSVALDO, MANSOUR, TAREK, S, DEHNHARDT, CHRISTOPH, M, KAPLAN, JOSHUA, AARON, ZASK, ARIE, CHEN, ZECHENG, VERHEIJEN, JEROEN, C, RICHARD, DAVID, J
Format Patent
LanguageEnglish
Serbian
Published 28.06.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS Compounds of formula I wherein: R 1 is and R 2 , R 4 , and R 6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Bibliography:Application Number: RS2019P000552